Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Sponsor: Icare Finland Oy
Terminated
A similar study has been published by other groups and this study is no longer needed.
This NA trial investigates Glaucoma and Ocular Hypertension and is currently terminated or withdrawn. Icare Finland Oy leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Feb 2026 — Mar 2026 [monthly]
Recruiting NA
Status: Unknown → Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting NA
-
Nov 2022 — Dec 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting NA
-
Apr 2022 — Sep 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Icare Finland Oy
- Nanodropper, Inc.
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .